Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
INBX

INBX - Inhibrx, Inc. Stock Price, Fair Value and News

$73.83+0.34 (+0.46%)
Market Closed

6/100

INBX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

6/100

INBX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$59.73

Target 3M

$67.19

Target 6M

$63.46

INBX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INBX Price Action

Last 7 days

-1.7%

Last 30 days

-6.9%

Last 90 days

-6.0%

Trailing 12 Months

503.2%

INBX RSI Chart

INBX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INBX Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

-16.22

Price/Sales (Trailing)

369.06

EV/EBITDA

-18.01

Price/Free Cashflow

-19.8

INBX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$59.73

Target 3M

$67.19

Target 6M

$63.46

INBX Fundamentals

INBX Revenue

INBX Earnings

INBX Profitability

Free Cashflow Yield

-5.05%

INBX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20233.7M5.3M8.6M11.9M
20227.3M5.5M3.8M2.1M
202112.9M10.5M7.2M7.2M
202013.1M13.0M13.0M12.9M
201900013.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Inhibrx, Inc.

INBX
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.
 CEO
 WEBSITEhttps://inhibrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES132

Inhibrx, Inc. Frequently Asked Questions

INBX is the stock ticker symbol of Inhibrx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Inhibrx, Inc. is 4.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check INBX's fair value in chart for subscribers.

The fair value guage provides a quick view whether INBX is over valued or under valued. Whether Inhibrx, Inc. is cheap or expensive depends on the assumptions which impact Inhibrx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INBX.

As of Wed Jan 28 2026, INBX's PE ratio (Price to Earnings) is -16.22 and Price to Sales (PS) ratio is 369.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INBX PE ratio will change depending on the future growth rate expectations of investors.